FAQ

avagacestat

Known as: (2R)-2-(N-((4-Chlorophenyl)sulfonyl)-N-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide, Pentanamide, 2-(((4-chlorophenyl)sulfonyl)((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoro-, (2R)- 
 

Topic mentions per year

Topic mentions per year

2012-2017
012320122017

Related topics

Related topics

1 relation

Broader (1)

BMS 708163

Related mentions per year

Related mentions per year

2010-2017
201020122014201620182020
avagacestat
BMS 708163

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies.
INTRODUCTION Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for… (More)
Is this relevant?
2017
2017
Inhibition of γ-Secretase Leads to an Increase in Presenilin-1
γ-Secretase inhibitors (GSIs) are potential therapeutic agents for Alzheimer’s disease (AD); however, trials have proven… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
OBJECTIVE To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2012
2012
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters…
BACKGROUND γ-Secretase inhibitors (GSIs) are being investigated for their potential to modify the progression of Alzheimer… (More)
Is this relevant?
2012
2012
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
BACKGROUND AND OBJECTIVES Avagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (A… (More)
Is this relevant?